Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 169-176

  Aucejo, Federico ^a   Kim, Richard ^a   Zein, Nizar ^a   Quintini, Cristiano ^a   Uso, Teresa Diago ^a   Lopez, Rocio ^a   Eghtesad, Bijan ^a   Fung, John ^a   Miller, Charles ^a   Yerian, Lisa ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER MORPHOLOGY; CANCER RISK; CHEMOEMBOLIZATION; CONTROLLED STUDY; EXPLANT; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SINUSOID; LIVER TRANSPLANTATION; LIVER VEIN; MALE; MILAN CRITERIA; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION; UPREGULATION;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67649207005     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21678     Document Type: Article

References (38)

1. Pang RWC, Poon RTP. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72:30-44.
2. Terada T, Nakanuma Y. Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Histopathology 1995;27:333-339.
3. Nakamura K, Zen Y, Sato Y, Kozaka K, Matsui O, Harada K, Nakanuma Y. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1α are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol 2007;10:1532-1546.
4. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
5. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004;130:307-319.
6. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, et al. Vascular permeability factor, fibrin, and the pathogenesis of the tumor stroma formation. Ann N Y Acad Sci 1992;667:101-111.
7. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999;30:1179-1186.
8. Dayanir V, Meyers R, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001; 276:17686-17692.
9. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008;14:1-14.
10. Roth P, Hammer C, Piguet AC, Ledermann M, Dufour JF, Waelti E. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target 2007;15:623-631.
11. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, et al. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005;11:960-963.
12. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;334:693-699.
13. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903.
14. Takimoto CH, Awada A. Safety and anti-tumor activity of Sorafenib in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-548.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2005; 42:1208-1236.
16. Pang R, Poon RT, Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151-167.
17. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004;11:1077-1084.
18. Poon RTP, Lau C, Pang R, Ng K, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007;14:1835-1845.
19. Poon RTP, Ng IOL, Lau C, Zhu LX, Yu WC, Lo CM, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001;233:227-235.
20. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376:62-66.
21. Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, et al. Expression of vascular endothelial growth factor receptors is closely related to the histological grade of
22. hepatocellular carcinoma. Oncol lRep 2006;16:3-10.
23. Zhu AX. Development of Sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008;112:250-259.
24. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T, Sugimachi K. The mechanisms of angiogenesis in hepatocellular
25. carcinoma: angiogenic switch during tumor progression. Surgery 2002;131:S135-S141.
26. Saftoiu A, Ciurea T, Banita M, Georgescu C, Comanescu V, Rogoveanu I, et al. Immunohistochemical assessment of angiogenesis in primary hepatocellular carcinoma. Rom J Gastroenterol 2004; 13:3-8.
27. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular
28. carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674-682.
29. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22:Sl08-S111.
30. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007;37:S115-S120.
31. Farinati F, Cardin R. Bortolami M, Burma P, Russo FP, Rugge M, et al. Hepatitis C virus: from oxygen free radicals to
32. hepatocellular carcinoma. J Viral Hepatol 2007;14:821-829.
33. Nasimuzzaman MD, Gulam W, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1α and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007;81:10249-10257.
34. Shweiki D,, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated
35. angiogenesis. Nature 1992;359:843-848.
36. Von Marschall Z, Cramer T, Hocker M, Finkenzeller G. Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001;48:87-96.
37. Suzuki H, Mori M, Kawaguchi C, Adachi M, Mjura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 1999;14:10871090.
38. Kulik LM, Atassi B, Van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-586.